Chemo infusion plus dual immunotherapy for pancreatic cancer with liver spread
Part of Cancer, Digestive system, Immune system & allergy clinical trials.
This trial combines a type of chemo given directly into the liver with two immunotherapy drugs to treat pancreatic cancer that has spread to the liver. The goal is to see if this combination can shrink the tumors and help you live longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have pancreatic cancer that has spread to the liver and has not been treated yet.
- You are generally in good health (able to do light activity, like walking).
- Your tumor and liver spots must have a good blood supply, which the doctors will check.
- You have not had chemo, targeted therapy, or immunotherapy for this cancer before.
- You have no serious heart, lung, or autoimmune conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new treatment combining tumor destruction with heat/cold (ablation) and an immunotherapy drug (PD-1) for people whose pancreatic cancer has spread to the liver. The goal is to help the immune system fight the cancer better.
This trial tests a new immunotherapy drug called ivonescimab combined with chemotherapy, with or without another experimental drug (AK117), for people with pancreatic cancer that has spread. The goal is to see if adding these therapies can help shrink tumors or slow the cancer's growth.
This trial tests a combination of immunotherapy (adebelimab) and chemotherapy drugs (irinotecan liposome, oxaliplatin, fluorouracil, and calcium folinate) as a first treatment for pancreatic cancer that has spread to the liver. The goal is to see if this combination is safe and effective.
This trial tests a combination of a chemotherapy drug (irinotecan liposome) plus an immunotherapy drug (addebelizumab) given before surgery to people with pancreatic cancer that can be fully removed. The goal is to see if this treatment reduces the chance of the cancer coming back and improves outcomes.
This trial compares two different chemotherapy combinations, each paired with immunotherapy and radiation, as the first treatment for locally advanced pancreatic cancer. It aims to see which combination works better.
This trial tests a combination of chemotherapy (Nal-IRI, 5-FU, leucovorin), an immunotherapy drug (PD-L1 inhibitor), and a targeted anti-angiogenic pill, with or without radiation (SBRT), as a second-line treatment for people with metastatic pancreatic cancer that has progressed after first-line therapy.
Hear when a new Pancreatic Cancer Liver Metastases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.